Application of NLRP3 inflammasome inhibitor
As an inhibitor targeting NLRP3 inflammasomes, potassium bismuth citrate solves the problem of poor treatment of various inflammatory diseases in the prior art, significantly alleviating the symptoms of related diseases. , new treatment options are provided.
Patent Information
- Application Number
- CN202411210162.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-30
- Publication Date
- 2024-12-03
AI Technical Summary
The prior art has not yet developed effective inhibitors targeting NLRP3 inflammasomes, resulting in limited clinical therapeutic effects on a variety of inflammatory diseases such as sepsis and multiple sclerosis.
Potassium bismuth citrate was used as an inhibitor specifically targeting NLRP3 inflammasomes, and its activation was inhibited by binding to NLRP3, reducing the production of Caspase-1 and IL-1β, significantly inhibiting the activation of the NLRP3 inflammatory pathway.
Potassium bismuth citrate can effectively inhibit the activation of NLRP3 inflammasomes and alleviate the symptoms of related diseases such as peritonitis, multiple sclerosis and septic shock, providing new therapeutic options and demonstrating its prevention and treatment of NLRP3-related diseases. potential applications.
Smart Images

Figure CN119055680A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medical technology, and specifically relates to an application of an NLRP3 inflammasome inhibitor. Background Art
[0002] The activation of NLRP3 inflammasome plays an important role in pyroptosis. In recent years, relevant studies have reported that NLRP3 inflammasome plays a key role in the occurrence and development of various diseases. NLRP3 inflammasome not only mediates important innate immune defense mechanisms, but also dysregulates NLRP3 inflammasome in the occurrence and development of many chronic inflammatory diseases (including multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease); in addition, the pathophysiological function of NLRP3 inflammasome also appears in several metabolic and neuroinflammatory diseases.
[0003] Sepsis is an extremely serious disease characterized by an uncontrolled immune response caused by severe infection, which in turn causes organ dysfunction. Globally, sepsis has become one of the leading causes of death in hospitals. The inhibitory effect of sepsis on the immune system is the result of a disruption of immune homeostasis; it is characterized by the release of anti-inflammatory cytokines, abnormal death of immune effector cells, and excessive proliferation of immunosuppressive cells. The use of antibiotics, fluid resuscitation, and organ support therapy has limited impact on the prognosis of patients with sepsis, and sepsis patients may die from immunosuppression or excessive inflammation caused by primary infection. In the acute phase of sepsis, NLRP3 is overactivated. ASC spot formation can be detected in neutrophils and monocytes of patients with sepsis, with a peak in neutrophils on the first day after the onset of sepsis and in monocytes on the sixth day, accompanied by the release of a large number of proinflammatory cytokines. The levels of IL-1β and IL-18 in the blood are increased, as well as the positive rate of caspase-1 with enzymatic activity in monocytes and the percentage of intracellular ASC spots. NLRP3 activation plays an important role in mediating the process of organ failure caused by sepsis. Current studies have shown that NLRP3 inhibitor treatment can reduce sepsis-induced organ damage in mice, such as acute kidney injury, cardiac insufficiency, acute lung injury, liver failure, and sepsis-related encephalopathy.
[0004] Multiple sclerosis is an autoimmune degenerative disease of the central nervous system characterized by demyelination, neuronal loss, and progressive neurological dysfunction. + T cells penetrate the blood-brain barrier and the blood-spinal cord barrier to cause inflammation, axonal demyelination, gliosis, and neurodegeneration. Current treatments for multiple sclerosis are limited, and new therapeutic strategies are needed to maintain remission or prevent disease progression. It has long been a consensus that the NLRP3 inflammasome acts by enhancing CD4+ The pathogenesis of multiple sclerosis is driven by the differentiation of T cells into Th1 and Th17 subsets. Loss of NLRP3 leads to reduced secretion of mature IL-1β and IL-18, which significantly inhibits the differentiation and response of Th1 and Th17. In the EAE model of multiple sclerosis, several NLRP3 inhibitors can improve the disease and reduce demyelination.
[0005] Inhibiting the activation of NLRP3 inflammasomes can effectively alleviate sepsis, peritonitis, multiple sclerosis and other diseases, so it is regarded as an important intervention target for the treatment of various inflammatory diseases. However, due to the safety and efficacy issues in preclinical trials, no inhibitors targeting NLRP3 are currently used in clinical practice. Therefore, it is necessary to screen and identify existing clinical drugs targeting NLRP3 inflammasomes, develop new uses for drugs, reduce drug development costs, and accelerate the entry of drugs into clinical practice, so as to provide candidate therapeutic drugs for the treatment of inflammation and related diseases targeting NLRP3 inflammasomes, further promote the development of the medical field, and bring good news to the treatment of patients with related diseases.
[0006] Gastrodenol (Bismuth tripotassium dicitrate, GAS) forms a glycoprotein-bismuth complex with gastrointestinal mucus, covering the gastrointestinal ulcer with a protective film; at the same time, it stimulates the secretion of epidermal growth factor and prostaglandin E2, thereby reducing the secretion of gastric acid and inducing the secretion of bicarbonate by the gastric mucosa, reducing the damaging effect of gastric acid on ulcers; in addition, GAS also has a direct inhibitory effect on Helicobacter pylori. However, no studies have reported the role of GAS in NLRP3-related diseases. Summary of the invention
[0007] Purpose of the invention: The technical problem to be solved by the present invention is to provide an application of NLRP3 inhibitors in view of the deficiencies in the prior art.
[0008] In order to solve the above technical problems, the present invention discloses an application of an NLRP3 inflammasome inhibitor. The specific technical solution is as follows:
[0009] The present invention provides an application of an NLRP3 inflammasome inhibitor in the preparation of a drug for preventing or treating cell pyroptosis diseases, wherein the NLRP3 inflammasome inhibitor is potassium bismuth citrate. The structural formula of potassium bismuth citrate is shown in the figure below:
[0010]
[0011] Wherein, the cell pyroptosis disease is any one of sepsis, multiple sclerosis or peritonitis. The cell pyroptosis diseases in the present invention also include gout, septic shock, ulcerative colitis and atherosclerosis.
[0012] Preferably, the sepsis is lipopolysaccharide-induced sepsis, the multiple sclerosis is myelin oligodendrocyte glycoprotein MOG-induced multiple sclerosis, and the peritonitis is microcrystalline sodium urate MSU-induced peritonitis.
[0013] Wherein, the potassium bismuth citrate is the only active ingredient in the medicine.
[0014] Among them, the potassium bismuth citrate is an inhibitor that specifically targets the NLRP3 inflammasome.
[0015] The binding energy between the potassium bismuth citrate and NLRP3 is less than -5 kcal / mol, and the potassium bismuth citrate has binding affinity with NLRP3.
[0016] The potassium bismuth citrate is used as an NLRP3 inflammasome inhibitor to inhibit the activation of NLRP3 inflammasome induced by lipopolysaccharide, nigericin or ATP.
[0017] The potassium bismuth citrate is a drug that inhibits intracellular ASC oligomerization, intracellular NLRP3 oligomerization, and intracellular NLRP3 ATPase activity.
[0018] Beneficial effects: Compared with the prior art, the present invention has the following beneficial effects:
[0019] (1) The present invention screened and discovered a new use of potassium bismuth citrate, a drug for clinical treatment of peptic ulcers. The present invention provides the use of potassium bismuth citrate as an inhibitor of NLRP3 inflammasomes. The present invention found that potassium bismuth citrate can inhibit the activation of classical inflammasomes induced by bacterial lipopolysaccharide combined with ATP, nigericin, and microcrystalline sodium urate. At the same time, it has a significant inhibitory effect in iBMDM, BMDM and THP-1 cells. Potassium bismuth citrate can reduce the production of Caspase-1p20 and IL-1βp17 caused by the activation of the NLRP3 inflammatory pathway. In addition, experimental studies have found that potassium bismuth citrate does not inhibit the AIM2 inflammasome pathway stimulated by bacterial lipopolysaccharide and Poly (dA: dT), and does not inhibit the NLRC4 inflammasome pathway stimulated by bacterial lipopolysaccharide and flagellin, proving the specific inhibitory effect on NLRP3 inflammasomes.
[0020] (2) The present invention provides the use of potassium bismuth citrate for preventing and treating NLRP3 inflammasome-related cell pyroptosis diseases, in particular: potassium bismuth citrate can prevent and treat peritonitis induced by microcrystalline sodium urate, and reduce the levels of inflammatory cells and inflammatory factors; potassium bismuth citrate can prevent and treat MOG-induced multiple sclerosis, reduce disease scores, alleviate spinal cord pathology and reduce the release of inflammatory factors; potassium bismuth citrate can reduce the mortality rate of septic shock induced by bacterial lipopolysaccharide and reduce the levels of inflammatory factors in serum.
[0021] Therefore, the present invention proves for the first time that potassium bismuth citrate may become a therapeutic drug for NLRP3-related diseases, providing a new option for the screening and reuse of clinical drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] The present invention will be further described in detail below in conjunction with the accompanying drawings and specific embodiments, and the above and / or other advantages of the present invention will become more clear.
[0023] Figure 1 A series of graphs showing that potassium citrate bismuth inhibits the activation of NLRP3 inflammasome in mouse macrophages. Figure 1 A is a graph showing the assessment of iBMDM cell viability using CCK-8 assay (n=4); Figure 1 BE is the concentration of IL-1β in the supernatant detected by ELISA (n=3); Figure 1 FI is the levels of pro-IL-1β, pro-caspase-1, and NLRP3 in iBMDM and BMDM cell lysates (LYS) and the levels of IL-1β and caspase-1 in the supernatant (SN) detected by Western blot analysis.
[0024] Figure 2 A series of images showing that potassium citrate inhibits GSDMD cleavage and pyroptosis in macrophages. Figure 2 A is immunofluorescence staining to detect live and dead cells; Figure 2 B is the proportion of PI-positive cells to total cells (n=5); Figure 2 CF is the LDH release rate graph; Figure 2 GJ is the Western blot analysis of GSDMD and GSDMD-NT in cell lysates.
[0025] Figure 3 A series of graphs showing that potassium citrate bismuth inhibits the activation of NLRP3 inflammasome in human macrophages. Figure 3 A is the concentration of IL-1β in the cell supernatant determined by ELISA (n=3); Figure 3 B is the concentration of LDH released by cells (n=4); Figure 3C is Western blot analysis of the expression of pro-IL-1β, pro-caspase-1, NLRP3, GSDMD, and GSDMD-NT in THP-1 cell lysates, and the expression of IL-1β and caspase-1 in the supernatant; Figure 3 D is an image of live and dead cells detected by immunofluorescence; Figure 3 E is the percentage of PI-positive cells to the total number of cells (n=6).
[0026] Figure 4 This is a diagram showing that potassium citrate specifically targets NLRP3. Figure 4 A is the analysis of IκBα, NF-κB, ERK, p38 and JNK and their phosphorylated proteins by Western blot analysis; Figure 4 B is a Western blot analysis of protein expression of NLRP3, pro-caspase-1, pro-IL-1β and ASC; Figure 4 C is a graph of LDH release rate after cells were stimulated with Poly(dA:dT) (n=3); Figure 4 D is a graph of LDH release rate after flagellin stimulation of cells (n=3); Figure 4 E is the protein expression of pro-IL-1β, pro-caspase-1, and NLRP3 in cell lysate and IL-1β and caspase-1 in cell supernatant after cells were stimulated with Poly(dA:dT) by Western blot analysis; Figure 4 F is Western blot analysis of the expression of pro-IL-1β, pro-caspase-1, and NLRP3 proteins in cell lysates and the expression of IL-1β and caspase-1 proteins in cell supernatants after flagellin stimulation of cells; Figure 4 G is the detection of ASC oligomers by DSS cross-linking assay; Figure 4 H is the determination of NLRP3 oligomers by Native-PAGE; Figure 4 I is for Lumi TM Luminescence was detected by luminescent ATP detection kit (n=3); Figure 4 J is a schematic diagram of the molecular docking of potassium bismuth citrate and NLRP3.
[0027] Figure 5 A series of images showing that potassium citrate bismuth improves sepsis in animal models. Figure 5 A is a flowchart for the construction of sepsis mouse model; Figure 5 B is the 72-hour survival rate of the sepsis mouse model; Figure 5 C is H&E staining of lung tissue; Figure 5 D is flow cytometry analysis of immune cells in the peripheral blood of sepsis mice 12 hours after modeling. Figure 5 D The left picture shows CD45 + CD11b+ 6G + Neutrophils, Figure 5 D The right picture shows CD45 + Ly6C + Monocytes; Figure 5 E is CD45 + Ly6C + Monocytes and CD45 + CD11b + 6G + The percentage and number of neutrophils in the total leukocytes (n=6); Figure 5 F is the concentration of IL-1β in mouse serum detected by ELISA (n=5). The Mantel-Cox test was used for statistical analysis of survival rate.
[0028] Figure 6 A series of graphs showing that potassium citrate improves disease progression in EAE mice. Figure 6 A is a schematic diagram of the construction of the EAE mouse model; Figure 6 B is the clinical score of EAE disease; Figure 6 C is the staining of NLRP3 inflammasome indicator ASC in spinal cord sections; Figure 6 D is H&E staining of spinal cord section; Figure 6 E is CD45 + CD4 + T cells, CD45 + CD8 + T cells, CD45 + CD11b - B220 + The percentage and number of B cells in the white blood cells (n=5); Figure 6 F is flow cytometry analysis of immune cells (CD45 + CD4 + T cells, CD45 + CD8 + T cells, CD45 + CD11b - B220 + B cells); Figure 6 G is RT-QPCR analysis of IL-1β, IL-17A and IL-6 mRNA levels in the spinal cord of EAE model mice (n=5).
[0029] Figure 7 A series of images showing that potassium bismuth citrate improves MSU-induced acute peritonitis in mice. Figure 7 A is a schematic diagram of the construction of the peritonitis mouse model; Figure 7 B is the flow cytometric analysis of CD45 in the peritoneal lavage fluid of MSU model mice+ CD11b + 6G + Neutrophils; Figure 7 C is CD45 in peritoneal lavage fluid + CD11b + 6G + The percentage of neutrophils in white blood cells and cell count (n=8); Figure 7 D is the level of IL-1β in peritoneal lavage fluid detected by ELISA (n=5).
[0030] Figure 8 It is the structural formula of bismuth potassium citrate. DETAILED DESCRIPTION
[0031] The above contents of the present invention are further described in detail below in the form of embodiments, but this should not be understood as the scope of the above subject matter of the present invention being limited to the following embodiments, and all technologies realized based on the above contents of the present invention belong to the scope of the present invention.
[0032] The experimental methods used in the following examples are all conventional methods unless otherwise specified, and the reagents, methods and equipment used are all conventional reagents, methods and equipment in the technical field unless otherwise specified.
[0033] In the following examples, the PBS buffer used, unless otherwise specified, is 1×PBS with a pH of 7.2-7.4.
[0034] Inflammatory diseases in the present invention include, but are not limited to, gout, sepsis, septic shock, ulcerative colitis, multiple sclerosis, atherosclerosis, etc.
[0035] The reagents used in the present invention and their sources are as follows: Bismuth tripotassium dicitrate Gastrodenol (GAS) used in the present invention was purchased from Selleck Company, item number S5866, with a structural formula as follows Figure 8 As shown. The certain concentrations of potassium bismuth citrate used in the following examples, unless otherwise specified, are all 1× PBS buffer solutions with a pH of 7.2-7.4. The sources of other reagents are shown in Table 1:
[0036] Table 1 Reagents used in the present invention and their sources
[0037]
[0038]
[0039] In the following examples, each experiment was repeated three times independently. GraphPad Prism 6.0 was used to analyze the data, and the data were expressed as mean ± standard deviation (SD). In order to test the statistical significance between two groups and multiple groups, unpaired t-test and one-way analysis of variance were used, respectively. Significance was defined as follows: *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
[0040] In the following animal experiments, the flow cytometry method is as follows: mouse cells are collected, red blood cells are lysed with 1× red blood cell lysis buffer for 5 minutes, centrifuged at 300g for 5 minutes, and the supernatant is removed, and the cells are stained at a dilution factor of 1:500, incubated at 4°C in the dark for 30 minutes, centrifuged at 300g for 5 minutes, and the supernatant is removed. 500 μL PBS is added to the centrifuge tube, and the cells are detected by flow cytometer and data are analyzed using FlowJo 10.6.2 software.
[0041] Example 1
[0042] The cells used in the present invention and their sources are shown in Table 2:
[0043] Table 2 Cells used in the present invention and their sources
[0044]
[0045] 1. iBMDM cell line
[0046] The iBMDM cells are obtained by injecting exogenous apoptosis-related spot-like protein ASC into RAW264.7 macrophages to induce ASC expression, thereby obtaining an iBMDM cell line (RAW264.7-ASC). The iBMDM cells are cultured in DMEM cell culture medium containing 10% v / v fetal bovine serum and 1% penicillin-streptomycin.
[0047] 2. BMDM primary cells
[0048] After receiving anesthesia, C57BL / 6J mice were euthanized by dislocation of the vertebrae, then immersed in 75% v / v ethanol solution for 5 minutes for disinfection and transferred to a clean bench. The hind limb muscle tissue was peeled off with forceps and the ends of the femur and tibia were cut off. The bone marrow was washed with DMEM medium, centrifuged at 300g for 5 minutes, the supernatant was discarded, and RPMI-1640 medium containing 10% fetal bovine serum, 1% penicillin-streptomycin and 20% v / v L929 cell culture supernatant containing macrophage colony stimulating factor was added. Half of the medium was changed after 4 days, and BMDM was differentiated and matured after 7 days.
[0049] 3.THP-1 cell line
[0050] Human monocytic cell line THP-1 cells were cultured in RPMI-1640 medium containing 10% v / v fetal bovine serum and 1% penicillin-streptomycin, and 100 nM PMA was added to induce differentiation for 16 hours. All cells (including iBMDM, BMDM and THP-1) were cultured in a 37°C cell culture incubator with 5% CO2.
[0051] Example 2 CCK-8 cell activity detection
[0052] iBMDM cells were cultured in a 96-well plate. After the cell density reached 85-90%, 2 μL of potassium citrate bismuth (0, 25, 50, 75, 100 μM) was used for 24 h (2 μL of PBS was used as a control). Then, a 10% volume concentration of CCK-8 solution was added to each well, and the cells were incubated at 37°C in a 5% CO2 incubator for 1 hour. The absorbance value was measured at a wavelength of 450 nm using an enzyme reader. The experimental results are shown in Figure 2. Figure 1 As shown in A, it can be seen from the figure that within a concentration of 100 μM, potassium bismuth citrate has no significant effect on cell growth, indicating that potassium bismuth citrate has good cell biosafety.
[0053] Example 3: Investigating whether GAS can inhibit the activation of NLRP3 inflammasome
[0054] In this example, enzyme-linked immunosorbent assay (ELISA) and Western Blot analysis were used to explore whether GAS can inhibit the activation of NLRP3 inflammasomes. The specific methods are as follows:
[0055] 1. Enzyme-linked immunosorbent assay (ELISA)
[0056] iBMDM, BMDM, and THP-1 cells were cultured in 6-well plates overnight. iBMDM and THP-1 cells were induced with DMEM medium containing LPS (200 μg / mL) for 4 hours, and then different concentrations of potassium citrate bismuth (0, 25, 50, 100 μM) were added at a volume ratio of 1:50-100 for 1 hour at 37°C. The cells were stimulated for 1 hour after replacing the medium with DMEM medium containing Nigericin (10 μM) or for 0.5 hours after replacing the medium with DMEM medium containing ATP (4 μM) to induce NLRP3 activation; the supernatant was collected. According to the instructions provided by the manufacturer, the proinflammatory cytokine IL-1β was detected in the cell culture supernatant using an ELISA kit, and the absorbance was measured using a microplate reader. The results are shown in Figure 2. Figure 1 B and Figure 1 As shown in C.
[0057] BMDM cells were induced with DMEM medium containing LPS (500 μg / mL) for 4 hours, and then different concentrations of potassium citrate bismuth (0, 10, 25, 50 μM) were added. After changing the medium, they were stimulated with DMEM medium containing Nigericin (10 μM) for 1 hour or with DMEM medium containing ATP (4 μM) for 0.5 hour. After the NLRP3 induction activation experiment, the supernatant was collected. According to the instructions provided by the manufacturer, the cytokine IL-1β was detected in the cell culture supernatant using an ELISA kit. The absorbance was measured with an enzyme-linked microplate reader, and the results were as follows: Figure 1 D and Figure 1 E. From Figure 1 B- Figure 1 E As can be seen, bismuth potassium citrate reduced the release of IL-1β in iBMDM cells and BMDM cells.
[0058] 2. Western Blot Analysis
[0059] After the cells were collected, the cell culture supernatant was loaded (SN), the cell pellet was used to extract the protein, and the cell pellet was added with NP-40 lysis buffer (LYS) containing protease inhibitors. The protein concentration was accurately determined using a BCA detection kit. Subsequently, the proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a PVDF membrane by electrotransfer technology. To ensure the reduction of nonspecific binding, the PVDF membrane was blocked with skim milk. Next, a specific primary antibody was added and incubated overnight on a shaker at 4°C. Subsequently, the membrane was washed with TBST solution and then incubated with an HRP-conjugated secondary antibody. The target band was developed using a Western Blot luminescent substrate, and the protein blot was recorded using GAPDH as an internal reference. The results are shown in Figure 2. Figure 1 As shown in FI, bismuth potassium citrate inhibited the release of activated IL-1β and caspase-1 in the supernatant, while having no effect on the expression levels of pro-caspase-1, pro-IL-1β, and NLRP3 in the cell lysate.
[0060] The above results indicate that potassium citrate inhibited the activation of NLRP3 inflammasome in mouse macrophages and reduced the secretion of IL-1β caused by its activation.
[0061] Example 4 Effect of Potassium Bismuth Citrate on Cell Pyroptosis
[0062] After the NLRP3 inflammasome activation treatment as described in Example 3 (BMDM cells stimulated by LPS were cultured with potassium citrate bismuth for 1 hour, and then the cells were stimulated with Nigericin for 1 hour), the culture medium was removed from BMDM and THP-1 cells, and Calcein AM / PI staining was performed. Specifically: propidium iodide (PI, concentration of 3 μg / mL) and calcein AM (Calcein AM, concentration of 2 ng / mL) solutions were added to PBS, added to the culture dish, incubated at 37°C for 15 minutes, and 5 fields were randomly captured using an immunofluorescence electron microscope. The obtained images were processed with Image J. The results of immunofluorescence staining showed that potassium citrate dose-dependently reduced the proportion of PI-positive BMDM cells ( Figure 2 A and Figure 2 B).
[0063] In the process of cell pyroptosis, the membrane perforating protein GSDMD forms holes in the cell membrane, which in turn causes the release of substances inside the cell. In order to quantify this process, this implementation uses the release of lactate dehydrogenase LDH as an indicator to assess the degree of cell membrane lysis. The specific method is as follows: After activating the NLRP3 inflammasome in iBMDM, BMDM, and THP-1 cells as described in Example 3, the cell supernatant is collected, and the absorbance is measured at 490nm according to the instructions of the LDH detection kit to detect LDH activity. The experimental results show that potassium bismuth citrate reduces the release of LDH caused by pyroptosis in BMDM or iBMDM cells ( Figure 2 CF); in addition, the results of Western Blot (GAPDH as internal reference) showed that potassium citrate inhibited the shearing of GSDMD, such as Figure 2 As shown by GJ.
[0064] In summary, potassium bismuth citrate can inhibit NLRP3 inflammasome-dependent pyroptosis in mouse macrophages, suggesting that it may play a role in inhibiting inflammatory responses.
[0065] Example 5 Effect of Potassium Bismuth Citrate on NLRP3 Inflammasome in Human Macrophage Cell Line THP-1 Cells
[0066] The above examples demonstrate that potassium bismuth citrate can inhibit the activation of NLRP3 inflammasomes and cell pyroptosis in mouse macrophage cell lines and primary cells; on the other hand, the present invention explores whether potassium bismuth citrate can inhibit the activation of NLRP3 inflammasomes and the cleavage of GSDMD in human macrophage cell line THP-1 cells. The experiment was carried out according to the treatment method of THP-1 cells described in Examples 3 and 4 (THP-1 cells stimulated by LPS were cultured with potassium bismuth citrate for 1 hour, and then the cells were stimulated with Nigericin for 1 hour). The experimental results are as follows: First, the ELISA results showed that potassium bismuth citrate inhibited the release of IL-1β ( Figure 3 A), Western Blot experiments confirmed that potassium citrate inhibited the release of activated IL-1β and caspase-1 in the supernatant of THP-1 cells, and did not affect the expression levels of other NLRP3 inflammasome components ( Figure 3 C); Next, the expression of GSDMD-NT and the level of LDH release were detected. As expected, potassium citrate also inhibited NLRP3-mediated cell pyroptosis in THP-1 cells ( Figure 3 B and Figure 3 Finally, this example used immunofluorescence staining Calcein AM / PI to detect live and dead cells, and the results were as follows Figure 3 D and Figure 3 E shows that potassium citrate bismuth dose-dependently reduced the proportion of PI-positive THP-1 cells.
[0067] Example 6
[0068] NF-κB is a key signal in the initiation step of the NLRP3 pathway. This example investigates whether potassium citrate bismuth affects the NF-κB signaling pathway. The specific method is as follows: When the iBMDM cells in a 6-well plate grow to 80-90% confluence, pretreat the iBMDM cells with 100 μM potassium citrate bismuth for 2 hours, then add 200 ng / mL of LPS to stimulate the cells for different times of 0, 5, 15, 30, 60, and 120 minutes, collect the cells for lysis and sample preparation, and then perform Western Blot detection. Figure 4As shown in A, the Western Blot results showed that potassium citrate did not inhibit the expression of IκBα, NF-κB, ERK, JNK, p38 and their phosphorylated proteins, indicating that potassium citrate did not affect the NF-κB signaling pathway. To further confirm these findings, in this example, iBMDM cells were pretreated with 100 μM potassium citrate according to the above method, and then the cells were stimulated with 200 ng / mL LPS for 4 hours, and the core components of the NLRP3 inflammasome, including pro-IL-1β, pro-caspase-1, ASC and NLRP3, were analyzed by immunoblotting; as expected, potassium citrate had no effect on the expression of these proteins ( Figure 4 B).
[0069] Example 7 Specificity of Potassium Bismuth Citrate in Inhibiting NLRP3
[0070] This example explores the specificity of potassium citrate in inhibiting NLRP3. This example uses potassium citrate to activate non-NLRP3 inflammasomes (AIM2 and NLRC4). The specific method is: after being treated with 200 ng / mL LPS and different concentrations (0, 25, 50, 100 μM) of potassium citrate for 1 hour, iBMDM cells are treated with Flagellin (2.5 μg / mL, stimulated for 2.5 hours) or Poly (dA: dT) (1 μg / mL, stimulated for 6 hours) to induce the activation of NLRC4 and AIM2 inflammasomes. LDH and Western Blot results show that potassium citrate has an effect on the release of LDH induced by AIM2 inflammasomes ( Figure 4 C) and the expression of activated caspase-1 and IL-1β in the supernatant ( Figure 4 E); Similarly, potassium citrate bismuth had an effect on NLRC4-induced LDH release ( Figure 4 D) and the expression of activated caspase-1 and IL-1β in the supernatant ( Figure 4 F) This confirms that bismuth potassium citrate does not affect the activation of AIM2 or NLRC4.
[0071] Example 8
[0072] In the activation process of NLRP3, ASC oligomerization is a key step in the subsequent activation of caspase-1. The present invention further explores whether the inhibitory effect of potassium citrate bismuth on NLRP3 inflammasome activation is mediated by inhibiting ASC oligomerization. Therefore, this embodiment uses DSS cross-linking experiments to detect ASC protein multimerization. iBMDM cells were cultured in 6-well plates to stimulate NLRP3 activation (specifically, iBMDM cells stimulated by LPS were cultured with potassium citrate bismuth for 1 hour, and then the cells were stimulated with ATP for 1 hour), and then the cells were lysed with NP-40 containing protease inhibitors on a shaker on ice for 30 minutes. The precipitate in the cell lysate was centrifuged at 6000g for 15 minutes at 4°C and incubated with 2mM DSS at room temperature for 30 minutes. Finally, Western blot analysis was performed. The experimental results show that, Figure 4 As shown in G, potassium citrate bismuth did not change the expression of ASC in cell lysate, but inhibited the formation of ASC oligomers.
[0073] Next, this example uses the naive-PAGE experimental technique to detect the effect of potassium citrate bismuth on NLRP3 inflammasome oligomerization, as follows: iBMDM cells were cultured overnight in a 6-well plate. After the NLRP3 induced activation experiment (specifically, iBMDM cells stimulated by LPS were cultured with potassium citrate bismuth for 1 hour, and then the cells were stimulated with ATP for 1 hour), the cells were lysed using NP-40 lysis buffer containing protease inhibitors in an ice shaker environment. The whole process lasted for 30 minutes to ensure that the cells were fully lysed; then centrifuged at 300g for 5 minutes, and the supernatant was collected. The supernatant was added to the naive gel loading buffer. Finally, a naive-PAGE test was performed. Similar to the DSS cross-linking experiment, potassium citrate also inhibited the formation of NLRP3 oligomers ( Figure 4 H).
[0074] In addition, this example also studies the effect of potassium citrate bismuth on endogenous NLRP3 ATPase activity. HEK293T cells transfected with human NLRP3 plasmid were cultured with different concentrations of potassium citrate bismuth (0, 25, 50, 100 μM) for 40 minutes, and then ATP was added to the reaction buffer and cultured at 37°C for 40 minutes. The amount of ATP converted to ADP was measured by Lumi TM The luminescent ATP detection kit was used for determination according to the method provided by the manufacturer. The results showed that potassium citrate inhibited the activity of NLRP3 ATPase, indicating that potassium citrate inhibited the oligomerization of NLRP3 in an ATPase-dependent manner ( Figure 4 I).
[0075] Finally, AutoDocktools was used in this example to perform a molecular docking test between potassium citrate bismuth and NLRP3. NLRP3 ID: 6NPY, from the PDB database. Pymol 2.3.0 was used to remove protein crystal water and original ligands. The protein structure was imported into AutoDocktools (v1.5.6) for hydrogenation, charge calculation, charge assignment, and atom type specification. The NLRP3 related parameters were set as follows: center_x = 87.015, center_y = 95.575, center_z = 91.600; search space: size_x: 60, size_y: 60, size_z: 60 (spacing per grid) ); Exhaustiveness: 10; The rest of the parameters were set to default values. PyMOL 2.3.0 was used to analyze the docking results of the interaction mode. The test results showed that the binding energy of potassium citrate bismuth to NLRP3 was -5.1 kcal / mol, indicating that it had good binding affinity ( Figure 4 J).
[0076] Example 9 Construction of sepsis mouse model
[0077] Eight-week-old C57BL / 6J mice (20–25 g) were purchased from the Model Animal Institute of Nanjing University. All mice were acclimated for one week before the study. All animal experiments were performed in accordance with the Animal Research: In Vivo Experiment Reporting Guide and in accordance with procedures approved by the Animal Care Committee of Nanjing Drum Tower Hospital.
[0078] In the context of Gram-negative bacterial infection, LPS triggers sepsis, leading to fatal endotoxemia and a sepsis cascade. The LPS-induced sepsis model in mice is one of the inflammatory diseases mediated by the NLRP3 inflammasome. So far, mechanistic studies have shown that inhibiting the assembly and activation of the NLRP3 inflammasome can prevent the inflammatory response typically seen in sepsis.
[0079] The sepsis animal model was established by injecting LPS (20 mg / kg) into C57BL / 6J mice. First, the present invention studied the therapeutic effect of potassium citrate bismuth on LPS-induced sepsis in mice. The mice were divided into a control group and a treatment group, each with 10 mice per group. Figure 5 As shown in A, 24 hours and 2 hours before LPS injection, the mice were intraperitoneally injected with potassium citrate bismuth (10 mg / kg, dissolved in PBS, treatment group) or an equal amount of PBS (control group), and the survival rate of the mice was recorded every 6 hours. The number of mice surviving in each group within 72 hours after modeling was observed and the survival rate was calculated. The mice in the control group died 12 hours after modeling, and the survival rate was 0% after 24 hours; the survival rate of the mice in the treatment group was significantly improved, reaching 80% ( Figure 5B). Next, the effect of potassium citrate on improving organ damage in mice caused by sepsis was investigated. After 12 hours of LPS stimulation, the mice were perfused with 4% paraformaldehyde, and the lung tissues were obtained and fixed for H&E staining. The experiment showed that potassium citrate could reduce the infiltration of inflammatory cells in the lung tissues of mice with LPS-induced sepsis ( Figure 5 C).
[0080] To further evaluate the effect of potassium citrate bismuth on peripheral inflammatory cells, blood was collected from the eyeballs 12 hours after LPS stimulation, and mononuclear cells isolated from peripheral blood were analyzed by flow cytometry. + Ly6C + Monocytes and CD45 + CD11b + 6G + The proportion and number of neutrophils ( Figure 5 D and E); The present invention also uses an ELISA kit to measure the expression of inflammatory factor IL-1β in serum. The ELISA results show that potassium citrate has a significant inhibitory effect on the release of inflammatory factor IL-1β ( Figure 5 F). These findings suggest that potassium citrate can effectively improve LPS-induced septic shock, alleviate immunosuppression and reduce the production of proinflammatory cytokines.
[0081] Example 10MOG 35-55 Establishment of EAE model induced in mice
[0082] Multiple sclerosis is an autoimmune disease of the central nervous system, and EAE is a classic animal model that simulates central nervous system demyelinating lesions and T cell responses in multiple sclerosis. Although multiple sclerosis is a complex disease, EAE reproduces the key pathological features of multiple sclerosis, such as axonal demyelination and inflammation. In this example, mice were divided into a control group and a treatment group, with 9 mice in each group. On day 0, an emulsion containing myelin oligodendrocyte glycoprotein MOG was subcutaneously injected into the back of C57BL / 6J mice (female, 8 weeks). 35-55(250 μg per mouse), Mycobacterium tuberculosis (400 μg per mouse), and complete Freund's adjuvant (50 μL per mouse). Pertussis toxin (500 ng per mouse) was injected intraperitoneally on days 0 and 2. The clinical score of EAE progression was evaluated daily and calculated on a scale of 0-5 as follows: 1, tail lameness or staggering gait, and high tail tension; 2, staggering gait, tail weakness (ataxia); 2.5, ataxia, partial paralysis of one limb; 3, complete paralysis of one limb; 3.5, complete paralysis of one limb and partial paralysis of the other limb; 4, complete paralysis of both limbs; 4.5, moribund; 5, death. Mice were intraperitoneally injected with potassium citrate bismuth (10 mg / kg, solvent is PBS) or an equal amount of PBS every day starting from the second day of emulsion injection until the peak of EAE disease ( Figure 6 A).
[0083] The progression of EAE was observed and evaluated daily, and clinical scores were calculated on a scale of 0-5. The mice in the control group began to develop the disease on the 16th day of modeling and reached the peak of the disease on the 23rd day, while the mice in the drug-treated group began to develop the disease on the 25th day ( Figure 6 B), The results showed that bismuth potassium citrate could delay the disease progression of EAE.
[0084] The present invention also investigated the effect of potassium bismuth citrate on the central nervous system of EAE model mice. At the peak of EAE disease, the mice were anesthetized and killed, perfused with PBS, and the spinal cords of the mice were collected and fixed for ASC antibody (lot number sc-514414) staining and H&E staining. The staining results showed that the ASC aggregation, a marker of spinal cord NLRP3 inflammasome activation, was significantly reduced ( Figure 6 C); Inflammatory cell infiltration and demyelinating lesions in the white matter of the spinal cord were significantly alleviated under the action of potassium citrate bismuth ( Figure 6 D); In order to further explore the effect of potassium citrate bismuth on various inflammatory cells in the central nervous system, the mouse brain was removed and flow cytometry analysis was performed. The experimental results showed that compared with the control group, CD45 + CD4 + T cells, CD45 + CD8 + T cells, CD45 + CD11b - B220 + The percentage and total number of B cells were significantly decreased ( Figure 6E and F); The H&E staining method described in Example 9 and this example is as follows: extract the lungs of the control group and the treatment group mice of the sepsis model and the spinal cords of the control group and the treatment group mice of the EAE model, rinse with PBS, and fix in 4% paraformaldehyde; then soak in 70%, 80%, 95%, and 100% ethanol by volume for 1 hour, and then soak in xylene for 30 minutes, repeat twice, fix the spinal cord tissue in paraffin and slice it, and set the thickness to 5μM. Soak the slide with tissue sections in xylene for 30 minutes, then dewax in 100%, 100%, 95%, 90%, 80, and 70% ethanol for 10 minutes, and finally rinse with water; stain with hematoxylin for 4 minutes, rinse with water for 10 minutes, then soak in hydrochloric acid ethanol for 3 seconds, rinse with water for 10 minutes, and stain with eosin for 1 minute. Then, the slides were placed in 100% and 100% ethanol for dehydration for 10 minutes respectively; finally, they were immersed in xylene for 0.5 hours, sealed and dried in a fume hood, and observed and photographed with an optical microscope.
[0085] Next, RT-QPCR was used to detect the expression of mRNA levels of various inflammatory factors in spinal cord tissue. The total RNA of EAE mouse spinal cord was extracted using the TRIzol method. The RNA concentration was detected using a NanoDrop 2000 spectrophotometer. Then, the PrimeScript RT kit was used for reverse transcription. The reaction was performed in a volume of 20 μL. Then, the cDNA was tested by real-time PCR using a real-time PCR detection system and SYBR Green Master Mix. -ΔΔCt The relative expression level of the gene was determined by the method, and GAPDH was used as an internal control. Each sample was repeated 3 times to obtain the average value. The primer sequences are shown in Table 3:
[0086] Table 3 Real-time PCR primer sequence list
[0087]
[0088] The results showed that the transcriptome expression levels of IL1b, IL6, and IL17a in the mice treated with potassium citrate were significantly decreased ( Figure 6 G). Taken together, these results indicate that potassium citrate can inhibit the inflammatory response in EAE and significantly improve the severity of EAE disease.
[0089] Example 11 Construction of acute peritonitis model in mice induced by microcrystalline sodium urate (MSU)
[0090] Intraperitoneal injection of MSU is a commonly used mouse model of acute peritonitis that can induce NLRP3-dependent inflammation, which is characterized by IL-1β production and a large influx of neutrophils into the peritoneal cavity. C57BL / 6J mice were divided into a control group and a treatment group, with 10 mice in each group. C57BL / 6J mice were intraperitoneally injected with potassium citrate bismuth (10 mg / kg, solvent is PBS) or an equal amount of PBS 24 hours before injection of MSU. The next day, potassium citrate bismuth (10 mg / kg, solvent is PBS) or PBS was injected again 1 hour later, and then the mice were intraperitoneally injected with 1 mg MSU (such as Figure 7 A). After 4 hours, the mice were anesthetized and killed, and the peritoneal cavity was lavaged with 4 mL of cold PBS. The peritoneal lavage fluid was centrifuged at 300 g for 10 minutes at 4°C, and the cells and supernatant were collected respectively. The cells were analyzed by flow cytometry, and the supernatant was detected by ELISA kit for IL-1β. The results showed that compared with the control group, the CD45 in the peritoneal lavage fluid of the mice in the drug group was significantly higher than that in the control group. + CD11b + 6G + Decreased number and proportion of neutrophils ( Figure 7 B and C); In addition, the level of IL-1β in the peritoneal lavage fluid supernatant of the drug-treated group was also significantly reduced ( Figure 7 D). These data suggest that bismuth potassium citrate can attenuate the activation of NLRP3 inflammasome and alleviate acute peritonitis induced by MSU.
[0091] The present invention provides an idea and method for the application of NLRP3 inflammasome inhibitors. There are many methods and approaches to implement the technical solution. The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention. All components not specified in this embodiment can be implemented using existing technologies.
Claims
1. Use of an NLRP3 inflammasome inhibitor in the preparation of a drug for preventing or treating pyroptosis-related diseases, wherein: The NLRP3 inflammasome inhibitor is potassium bismuth citrate.
2. The use according to claim 1, characterized in that: The cell pyroptosis disease is any one of sepsis, multiple sclerosis or peritonitis.
3. The use according to claim 2, characterized in that: The sepsis is lipopolysaccharide-induced sepsis.
4. The use according to claim 2, characterized in that: The multiple sclerosis is multiple sclerosis induced by myelin oligodendrocyte glycoprotein MOG.
5. The use according to claim 2, characterized in that: The peritonitis described is peritonitis induced by microcrystalline sodium urate.
6. The use according to claim 1, characterized in that: The bismuth potassium citrate is the only active ingredient in the medicine.
7. The use according to claim 1, characterized in that: The bismuth potassium citrate is an inhibitor that specifically targets the NLRP3 inflammasome.
8. The use according to claim 7, characterized in that: The binding energy between the potassium bismuth citrate and NLRP3 is less than -5 kcal / mol, and the potassium bismuth citrate has binding affinity with NLRP3.
9. The use according to claim 1, characterized in that: The potassium bismuth citrate is used as an NLRP3 inflammasome inhibitor to inhibit the activation of NLRP3 inflammasome induced by lipopolysaccharide, nigericin or ATP.
10. The use according to claim 1, characterized in that: The bismuth potassium citrate is a drug that inhibits intracellular ASC oligomerization, inhibits intracellular NLRP3 oligomerization, and inhibits the ATPase activity of intracellular NLRP3.
